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The standard drug development process for antimalarials
and other drugs uses weight-based dosing (mg/kg) to pre-
dict blood concentrations of the drug, and hence their
effect. Consequently, the current World Health Organiza-
tion Guidelines for the treatment of malaria [1] provide
target doses and therapeutic dose ranges in mg/ kg/day.
However, in resource-poor settings, age-based dosing is
often employed instead of weight-based dosing because of
the scarcity of correctly functioning weighing scales out-
side of clinical settings. Due to the wide variation in weight
by age this approach inevitably results in over- and under-
dosing of a proportion of the population.
We have recently developed a modelling method to
create statistically robust global and regional malaria-spe-
cific weight-for-age references representative of the
malaria-endemic countries [2] and employed it to predict
optimized age-based regimens for artemisinin-based
combination therapies (ACTs) for case management of
uncomplicated malaria (unpublished). The presented
work now assesses the robustness of these age-based
regimens using an in silico model of antimalarial drug
treatment to predict treatment outcome based on indivi-
dual infection parameters such as parasite numbers, var-
iation in patient pharmacokinetics, and parasite variation
in their drug sensitivity [3]. This extended pharmacoki-
netic/pharmakodynamic model for ACTs allowed us to
investigate extreme treatment scenarios in a large num-
ber of patients over long follow-up periods that for ethi-
cal reasons could not be applied in clinical trials: typical
examples include poor adherence (e.g. delayed, reduced
or missed doses) or administration of doses above or
below recommended therapeutic dose ranges and parti-
cularly in most vulnerable individuals such as infants and
young children. Pharmacological modelling of antimalar-
ial treatment cannot replace the gold standard of clinical
trials, but the model outputs can identify patient groups
that are at higher risk of treatment failure due to under-
dosing or adverse events due to over-dosing.
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